Skip to content

Lariva Business

Lariva Blog

Menu
  • Privacy Policy
  • Tech Sharing
  • animate sharing
  • Science Sharing
  • Happening
Menu

Visus Therapeutics receives US$20 million to develop eye drops that can correct vision loss

Posted on August 13, 2021 by William

Vision therapy, A startup company based in Seattle, is developing a presbyopia correction eye drops, Raised 20 million US dollarsThe new cash was received within six months after the company raised $36 million. Supporters of this round include LSP, Sage Partners, Johnson & Johnson Innovation, etc.

The company’s main asset, BRIMOCHOL, is a once-daily eye drop designed to treat Presbyopia, A vision condition caused by aging that may make tasks such as reading difficult. According to the company, it affects approximately 123 million adults in the United States. Existing treatments include glasses, contact lenses or surgery.

Visus was founded in 2019 and is led by the CEO Ben BergoHe previously co-founded Lumos Diagnostics and Seattle-based Nohla Therapeutics. He was recently the executive officer of Planet Innovation.

Recent Posts

  • F5 About 100 jobs will be cut due to the “current macroeconomic environment”
  • Neoriver decoration lights up Christmas
  • Naveen Jain’s microbiome and diagnostics startup Viome is raising more money
  • Cutting the wearable display in half is more difficult and easier than it looks
  • Oculus Studios acquired Camouflaj, a Seattle regional studio behind “Iron Man VR”
©2023 Lariva Business | Design: Newspaperly WordPress Theme